STORM THERAPEUTICS
Targeting pathways that modify RNA to deliver novel cancer therapeutics.
STORM THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2015-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.stormtherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
+44 (0)1223 804174
Total Funding:
69.58 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon Google Tag Manager Google Analytics SSL By Default Global Site Tag ReCAPTCHA Google Universal Analytics
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Current Advisors List
Current Employees Featured
Founder
Investors List
M Ventures
M Ventures investment in Series B - Storm Therapeutics
Fast Track Initiative, Inc.
Fast Track Initiative, Inc. investment in Series B - Storm Therapeutics
Seroba Life Sciences
Seroba Life Sciences investment in Series B - Storm Therapeutics
Pfizer Venture Investments
Pfizer Venture Investments investment in Series B - Storm Therapeutics
UTokyo Innovation Platform
UTokyo Innovation Platform investment in Series B - Storm Therapeutics
Cambridge Innovation Capital
Cambridge Innovation Capital investment in Series B - Storm Therapeutics
Taiho Ventures
Taiho Ventures investment in Series B - Storm Therapeutics
IP Group
IP Group investment in Series B - Storm Therapeutics
Innovate UK
Innovate UK investment in Grant - Storm Therapeutics
M Ventures
M Ventures investment in Series A - Storm Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2023-11-01 | STORM Therapeutics Appoints Marguerite Hutchinson, J.D., as Chief Business Officer |
| 2022-09-07 | STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer |
Official Site Inspections
http://www.stormtherapeutics.com Semrush global rank: 10.97 M Semrush visits lastest month: 175
- Host name: web35.extendcp.co.uk
- IP address: 79.170.40.35
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
More informations about "Storm Therapeutics"
STORM Therapeutics - Overview, News & Similar companies
Feb 22, 2024 STORM Therapeutics contact info: Phone number: +44 2039509144 Website: www.stormtherapeutics.com What does STORM Therapeutics do? STORM Therapeutics, …See details»
STORM Therapeutics Limited - LinkedIn
STORM Therapeutics is a biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases.See details»
Harnessing the power of RNA epigenetics - STORM Therapeutics
Jerry has over 30 years of biotechnology leadership, scientific innovation, creative deal-making, and financing experience. With broad disease-area expertise and a specialty in oncology …See details»
Storm Therapeutics - Company Profile - Tracxn
Dec 15, 2024 Storm Therapeutics - Developer of small molecule cancer drugs targeting RNA-modifying enzyme. Raised a total funding of $98.3M over 9 rounds from 17 investors. Valued …See details»
Press releases - stormtherapeutics.com
Nov 11, 2024 [email protected]. Optimum Strategic Communications Hana Malik, Zoe Bolt, Elena Bates Tel: +44 (0)203 882 9621 [email protected] NOTES TO …See details»
STORM Therapeutics - Cambridge Innovation Capital
Cambridge Innovation Capital is a leading Series A investor in the Cambridge ecosystem. We were born out of a unique relationship with the University of Cambridge and we maintain …See details»
STORM Therapeutics - PitchBook
STORM Therapeutics General Information Description. Operator of a biotechnology and drug discovery company intended to develop small molecule therapies for RNA modification enzymes for use in the treatment of cancer …See details»
STORM Therapeutics - Products, Competitors, Financials, …
STORM Therapeutics Presents New Clinical Data on its First-in-Class METTL3 Inhibitor STC-15 at SITC 2024. Nov 12, 2024. Gene expression data shows upregulation of innate immunity …See details»
Storm Therapeutics - Craft
Storm Therapeutics has 5 employees across 2 locations and $21.37 m in total funding,. See insights on Storm Therapeutics including office locations, competitors, revenue, financials, …See details»
Storm Therapeutics Company Profile: Overview and Full News …
Stormtherapeutics.com. Pharmaceuticals Life Sciences Oncology Medical Device. Overview: Storm Therapeutics. Storm Therapeutics is a clinical stage biotechnology company based in …See details»
Storm Therapeutics - VentureRadar
Pioneers RNA epigenetics with STC-15, an oral small molecule targeting METTL3, showing promise in tumor inhibition and immune response. " STORM Therapeutics is a University of …See details»
Harnessing the power of RNA epigenetics - STORM Therapeutics
STORM Therapeutics is a pioneer in the field of RNA epigenetics. We are an emerging biotechnology company in Cambridge, UK, focused on developing small molecule inhibitors of …See details»
Storm Therapeutics - Crunchbase Company Profile & Funding
STC-15: An oral small molecule inhibitor of the RNA methyltransferase METTL3, used in oncology to inhibit tumor growth and activate anti-cancer immune responses.See details»
STORM Therapeutics Presents New Clinical Data on its First-in …
Nov 11, 2024 For more information, please visit www.stormtherapeutics.com. About STC-15 ... hosted by the leading member-driven organization focused on cancer immunotherapy, SITC. …See details»
STORM Therapeutics Presents New Clinical Data on its First-in …
Nov 11, 2024 For more information, please visit www.stormtherapeutics.com. About STC-15 ... hosted by the leading member-driven organization focused on cancer immunotherapy, SITC. …See details»
Tony Kouzarides, Founder of STORM Therapeutics, Awarded British ...
Jun 17, 2024 STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, is delighted to announce …See details»
Press releases - STORM Therapeutics
Aug 9, 2023 For more information, please visit www.stormtherapeutics.com. About STC-15. STORM’s lead clinical program STC-15 is a first-in-class inhibitor of RNA modification and is …See details»
Press releases - STORM Therapeutics
Jan 25, 2023 For more information, please visit www.stormtherapeutics.com. About STC-15 STORM’s lead clinical program STC-15 is a first-in-class inhibitor of RNA modification and is …See details»
Press releases - STORM Therapeutics
Dec 14, 2022 For more information, please visit www.stormtherapeutics.com About STC-15 STORM’s lead clinical program STC-15 is a potential first-in-class inhibitor of RNA …See details»